Semax and neurotransmitters: dopamine, serotonin, and others

Semax affects neurotransmitters such as dopamine, norepinephrine, and serotonin.

Semax acts on multiple neurotransmitter systems simultaneously. Documented effects include influences on serotonin, dopamine, GABA, glycine, acetylcholine, and norepinephrine, making it one of the most broadly acting synthetic peptides studied in modern neuroscience. Neurotransmitters are chemicals by which nerve cells communicate with each other. Each of them performs a different function – regulating mood, memory, movement, stress responses, and general brain function.

Semax stands out due to its mechanism of action. Unlike most conventional drugs, it does not directly activate or block one specific receptor. It acts as a neuromodulator, precisely regulating the sensitivity of existing neurotransmitter systems without flooding them with artificial signals. This can be compared to a dimmer switch rather than a simple on/off switch.

It is this ability to fine-tune that is considered the basis for both Semax's favorable safety profile and its broad neuroprotective and cognitive action. Available scientific evidence comes mainly from animal studies, with a limited but promising number of clinical data from human trials. The involvement of individual neurotransmitter systems in Semax's overall action profile remains an active area of research.

Does Semax affect dopamine?

Semax affects the dopaminergic system, however, its action is indirect and modulatory – not direct or constant. Dopamine is a neurotransmitter closely related to motivation, reward, movement, and the brain's response to pleasant experiences.

Under normal resting conditions, Semax administered alone does not significantly alter dopamine levels in either brain tissue or extracellular fluid. It also does not affect the levels of two major dopamine breakdown products—DOPAC and HVA—in the striatum, a brain region responsible for movement and reward processing [1].

However, the situation changes when Semax is administered before a dopamine-activating substance. In microdialysis studies – a technique involving the implantation of a miniature probe into the brain to measure cerebrospinal fluid composition in real-time – Semax administered 20 minutes before D-amphetamine caused a significantly higher peak dopamine concentration than amphetamine alone. Simultaneously, a more pronounced decrease in DOPAC levels was observed, indicating more intense dopamine release and utilization [2].

The results of behavioral studies in mice confirmed these observations. The combination of Semax and D-amphetamine increased the animals’ motor activity to 261% of the baseline value, whereas amphetamine alone reached only 182% [2]. This confirms that Semax significantly enhances the dopamine system’s response to stimulation.

Simple analogy: Semax works like turning up the volume on a speaker. When music is playing, it sounds louder – but just turning up the volume doesn't make the music start playing on its own. The dopamine system becomes more reactive, but Semax doesn't trigger dopamine release by itself.

This profile of action is consistent with the observation that Semax does not appear to induce addictive behaviors or lead to increasing dependence of the dopamine system on its presence. The exact mechanism of this enhancing effect has not yet been fully elucidated. Researchers suggest that it may involve melanocortin receptors influencing the excitability of dopaminergic neurons or indirect effects through the serotonin system, which regulates dopamine circuits.

All current data regarding Semax and dopamine come exclusively from animal studies. There is no direct evidence from human studies to date.

Does Semax affect serotonin?

Semax has measurable and repeatable effects on the serotonin system, with a particularly pronounced increase in serotonergic activity in the striatum. Serotonin is a neurotransmitter responsible for regulating mood, anxiety, sleep, and emotional well-being.

In rat striatal tissue, Semax administered at a dose of 0.15 mg/kg via intraperitoneal injection caused a significant increase in tissue levels of 5-HIAA by approximately 25% 2 hours after administration [1]. 5-HIAA is the main breakdown product of serotonin—higher levels of 5-HIAA indicate increased serotonin production and consumption.

Real-time measurements using microdialysis revealed an even more pronounced effect. Extracellular levels of 5-HIAA in the fluid surrounding brain cells gradually increased to approximately 180% of the baseline value within 1–4 hours after Semax administration [1]. This sustained increase suggests that Semax enhances the release and metabolism of serotonin in this brain region, rather than merely slowing its clearance.

Serotonergic effects may partially explain the documented anxiolytic and antidepressant properties of Semax. In animal studies, chronic administration of Semax for 10–14 days induced behavioral changes in rats indicative of reduced anxiety and antidepressant-like effects. Researchers attributed this, at least in part, to the activation of the serotonergic system and increased production of BDNF in the hippocampus [3].

Furthermore, in a model where rat neonates were exposed to fluvoxamine—an SSRI drug that alters serotonin processing during early brain development—administration of Semax reduced anxiety-like behaviors, improved learning abilities, and normalized disrupted brain chemical levels in the affected animals [4]. This suggests that Semax may help restore balance to the serotonin system when it is disrupted during critical developmental periods.

The precise receptor mechanisms underlying this normalization are not yet fully understood. All available data on the serotonergic action of Semax come from animal studies.

Does Semax affect GABA?

Semax directly modulates the GABAergic system – one of the brain's main inhibitory neurotransmitter systems. GABA, or gamma-aminobutyric acid, is the brain's primary inhibitory neurotransmitter. It reduces nerve cell activity and helps maintain a state of calm and balance.

Evidence for Semax's action on GABA comes from two types of studies: electrophysiological, which measure the actual electrical activity of nerve cells, and radioligand binding studies, where radioactively labeled molecules help determine where and how a substance binds to receptors.

In electrophysiological experiments on isolated rat brain neurons, Semax at a concentration of 1 micromole increased the GABA-evoked electrical currents in cerebellar Purkinje cells to approximately 147% of their normal level [5]. Purkinje cells are specialized nerve cells in the cerebellum—the part of the brain responsible for movement coordination and balance. The potentiating effect developed gradually and did not subside easily after Semax was removed from the preparation. This indicates a mechanism of action via intracellular signaling pathways, known as second-messenger systems, rather than through the direct opening of GABA-gated ion channels.

Radioligand binding studies confirmed that Semax affects both high- and low-affinity GABA binding sites on rat cerebrocortical neuron membranes. The effects were dose-dependent and varied depending on the specific binding site and whether the animal was under stress [6]. Under conditions of acute immobilization stress, pre-administered Semax modified stress-induced changes in GABA receptor binding, although it did not completely prevent them [6].

It is worth noting that other synthetic peptides structurally similar to Semax, including ACTH(6-9)PGP and ACTH(7-10)PGP, have also shown activity at GABA receptors. This suggests that the ability to modulate the GABAergic system is a common feature of the entire class of ACTH-derived peptides, rather than a phenomenon unique to Semax [6].

GABAergic effects likely contribute to Semax's anti-anxiety properties and its ability to protect brain cells during excitotoxic damage – a type of damage caused by overstimulation of neurons. However, this relationship requires further direct research. All data concerning GABA comes from animal studies and laboratory cell cultures.

Does Semax affect glycine?

Semax inhibits glycinergic neurotransmission in specific areas of the brain – which is an important complement to its enhancing effect on the GABAergic system. Glycine is another inhibitory neurotransmitter that, like GABA, reduces neuronal activity, but it acts through different receptors and is particularly active in the hippocampus and spinal cord.

In the same electrophysiological study that analyzed GABA currents, Semax at concentrations of 0.1 and 1 micromole reduced the amplitude of glycine-activated chloride currents in hippocampal pyramidal neurons —the brain’s primary memory center—to approximately 68% and 43% of their normal levels, respectively [5]. The effect was concentration-dependent: the higher the concentration of Semax, the greater the inhibition of glycine receptor activity.

Similar to the effect on GABA, the inhibition developed slowly and was difficult to reverse, again suggesting a second messenger-based mechanism rather than direct receptor blockade.

The fact that Semax simultaneously increases GABA activity in one brain region and inhibits glycine activity in another indicates a complex, regionally specific regulatory role. Instead of globally inhibiting or exciting the brain, Semax adjusts the balance of inhibitory neurotransmission depending on the area it acts upon. This may contribute to its specific effects on neuronal excitability and synaptic plasticity – the brain's ability to strengthen and weaken connections between nerve cells.

These results are based solely on electrophysiological data from isolated rat neurons.

Does Semax affect acetylcholine?

Semax modulates the cholinergic system – both through direct interaction with receptors and indirectly by influencing the survival of acetylcholine-producing neurons. Acetylcholine plays a crucial role in learning, memory, attention, and muscle control. It is also the neurotransmitter most affected in Alzheimer's disease.

Radioligand binding studies using radioactively labeled acetylcholine have confirmed that Semax dose-dependently modulates the binding of acetylcholine receptors in rat brain preparations [6]. At the cellular level, Semax increased the survival of cholinergic neurons in the basal forebrain—a group of nerve cells that produce acetylcholine, key for memory and attention—in primary cultures by approximately 1.5 to 1.7 times [7]. It also stimulated the activity of choline acetyltransferase—an enzyme responsible for acetylcholine synthesis within neurons—in basal forebrain tissue cultures at a concentration of 100 nanomolar [7]. Importantly, these effects were selective: Semax did not affect the total number of GABAergic neurons or other nerve cells in the same cultures, suggesting a specific targeting of cholinergic neurons.

Electrophysiological studies provided additional information. The inhibitory effect of Semax on the electrical activity of cat's cerebral cortex neurons was associated with the stimulation of M-cholinergic receptors, i.e., muscarinic receptors, in more than half of the studied cases [8]. This suggests that muscarinic receptor activation plays a significant role in the neuromodulatory action of Semax at the cerebral cortex level.

Semax's ability to support cholinergic neuron survival, increase acetylcholine synthesis, and modulate muscarinic receptors allows its cholinergic action to be considered a potentially important component of its pro-cognitive effect – especially in states of cholinergic deficiency. All available data comes exclusively from animal studies and cell cultures.

Does Semax affect norepinephrine?

Evidence for Semax's effect on norepinephrine – also known as noradrenaline – is more limited and largely indirect compared to its impact on other neurotransmitter systems. Norepinephrine regulates alertness, attention, stress response, and blood pressure.

Early studies on the structural precursor of Semax – the analog of ACTH(4-7)-Pro-Gly-Pro – showed that its administration lowered the content of noradrenaline in the cerebral cortex and other brain areas. It also normalized the asymmetric distribution of noradrenaline between the right and left hemispheres, without significantly affecting the distribution of serotonin [9]. In studies following resuscitation after hemorrhagic shock – a life-threatening condition caused by severe blood loss – intravenous Semax affected the dynamics of biogenic amines in the brainstem and spleen during the recovery period. In these studies, the effects on the serotonergic system were more pronounced than on the catecholaminergic systems, which include both norepinephrine and dopamine [10].

Research on prenatal hypoxia has shown that a lack of oxygen before birth disrupts the development of the norepinephrine and dopamine systems in the brains of newborns. Nasal administration of Semax to pregnant females prevented these disturbances in catecholamine levels in the central nervous system of the offspring during the postnatal period [11].

Available data suggest that Semax affects noradrenergic system activity, particularly under conditions of stress, hypoxia, or other pathological challenges. However, these effects are less direct and less consistently documented than its serotonergic or GABAergic actions. To date, no studies have directly measured extracellular norepinephrine concentrations in response to Semax using microdialysis or similar real-time measurement techniques, which represents a significant gap in the current evidence base. All available data come from animal studies.

Does Semax affect cortisol and the HPA axis?

Semax does not stimulate cortisol production and is classified as a non-hormonal peptide – it does not exhibit the steroidogenic activity of its parent hormone, ACTH. Early pharmacological studies confirmed that, unlike ACTH(5-10), the analog ACTH(4-7)-PGP did not exhibit steroidogenic or melanocyte-stimulating activity, which formed the basis of its non-hormonal classification from its inception [12].

Instead of activating the HPA axis—the central stress hormone system running from the hypothalamus through the pituitary gland to the adrenal glands—Semax appears to suppress its overactivity under conditions of chronic stress. In a model of chronic unpredictable stress in male rats, Semax treatment reversed stress-induced adrenal hypertrophy—an abnormal enlargement of these glands, which is a reliable physical indicator of chronic HPA axis hyperactivity [13]. At the same time, Semax also reversed anhedonia, which is the loss of the ability to feel pleasure, inhibited weight gain, and reduced hippocampal BDNF levels—all induced by chronic stress [13].

At the hypothalamic level – the brain region initiating the stress hormone cascade – Semax administration before stress exposure reduced c-Fos expression in the paraventricular nucleus of the hypothalamus in stress-susceptible rats [14]. C-Fos is a protein used as a biological marker of cell activation. Lower levels of c-Fos in this region indicate weaker hypothalamic activation in response to stress stimuli.

In the social stress model, Semax also demonstrated anti-inflammatory effects on the immune system: it lowered pro-inflammatory signaling protein concentrations of IL-1β and IL-6, restored IL-4 levels, and inhibited the activity of TGF-β1 and TNF-α [15]. This profile is consistent with the action of a substance that reduces, rather than exacerbates, stress-induced activation of the HPA axis and the immune system.

Studies confirm this, where rats subjected to immobilization stress and receiving Semax at doses of 50 and 150 micrograms per kilogram of body weight showed lower serum corticosterone concentrations – corticosterone is the rodent equivalent of human cortisol – as well as less stress-induced structural damage to the colon wall [16]. Data from human studies regarding these effects on the HPA axis remain limited to indirect clinical observations.

How does Semax modulate multiple neurotransmitter systems simultaneously?

Semax affects multiple neurotransmitter systems simultaneously through three interconnected mechanisms: direct receptor interactions, indirect effects via BDNF and neurotrophin signaling, and broad regulation of gene expression related to neurotransmission. This is one of the most interesting questions about this peptide – how can one small molecule act on so many systems at once.

At the gene expression level, RNA sequencing analysis in a stroke model in rats showed that Semax reactivated genes associated with neurotransmission that were silenced by ischemia and reperfusion – damage that occurs after blood flow to brain tissue is cut off and then restored. Semax effectively restored the expression patterns of these genes to a level close to that of healthy tissue [17].

Under conditions of acute stress, administration of Semax induced changes in the activity of over 1500 genes in the hippocampus. Both Semax and the related peptide ACTH(6-9)PGP increased the activity of stress-downregulated genes and decreased the activity of stress-upregulated genes [18]. This represents a broad, systemic correction of stress-disrupted neurotransmission patterns.

The concept of a synacton helps explain this multi-system reach. A synacton is Semax along with its active breakdown products – HFPGP and PGP – acting as an integrated regulatory complex. Each component interacts with distinct, yet partially overlapping, binding sites on neuronal cell membranes [19]. Together, they exert a pharmacological effect broader than what any single fragment could achieve on its own. This multi-directional action is characteristic of natural brain regulatory peptides and distinguishes Semax from conventional drugs with a single therapeutic target.

Understanding how all these effects integrate and interact in humans remains an important priority for future clinical research.

Disclaimer

This article is for educational and informational-scientific purposes only and should not be interpreted as medical advice, diagnosis, therapeutic recommendation, or a claim regarding the efficacy of Semax in treating any medical condition. Semax remains an investigational compound in most countries, including the United States and most European countries, and is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for treating any medical condition. It is approved and clinically used in Russia and some Eastern European countries. Most of the evidence presented in this article is derived from preclinical animal studies and a limited number of clinical studies in humans, many of which originate from Russian-language scientific literature. Additional well-designed clinical trials are needed to more accurately establish the safety, efficacy, mechanisms of action, and long-term effects of Semax in humans.